Micro-dosing

Phase 0 approaches evaluate subtherapeutic exposures of new drugs. Beyond assessment of pharmacokinetics it can include understanding of mechanism of action and pharmacodynamics. Phase 0 approaches have the potential to improve preclinical candidate selection and enable safer, cheaper, quicker and more informed developmental decisions.